

Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Growth 2023-2029

<https://marketpublishers.com/r/G8A5776EFA26EN.html>

Date: January 2023

Pages: 99

Price: US\$ 3,660.00 (Single User License)

ID: G8A5776EFA26EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

LPI (LP Information)' newest research report, the “Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Forecast” looks at past sales and reviews total world Glucagon-like peptide 1 (GLP-1)-based Therapies sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon-like peptide 1 (GLP-1)-based Therapies sales for 2023 through 2029. With Glucagon-like peptide 1 (GLP-1)-based Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Glucagon-like peptide 1 (GLP-1)-based Therapies industry.

This Insight Report provides a comprehensive analysis of the global Glucagon-like peptide 1 (GLP-1)-based Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon-like peptide 1 (GLP-1)-based Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon-like peptide 1 (GLP-1)-based Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Glucagon-like peptide 1 (GLP-1)-based Therapies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon-like peptide 1 (GLP-1)-based Therapies.

The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Glucagon-like peptide 1 (GLP-1)-based Therapies players cover Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Segmentation by application

Hospital

Pharmacy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Novo Nordisk

AstraZeneca

Eli Lilly

GSK

Sanofi

Bristol-Myers Squibb

Key Questions Addressed in this Report

What is the 10-year outlook for the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?

What factors are driving Glucagon-like peptide 1 (GLP-1)-based Therapies market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Glucagon-like peptide 1 (GLP-1)-based Therapies market opportunities vary by end market size?

How does Glucagon-like peptide 1 (GLP-1)-based Therapies break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Country/Region, 2018, 2022 & 2029

2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type

- 2.2.1 Exenatied
- 2.2.2 Liraglutide
- 2.2.3 Lixisenatide
- 2.2.4 Albiglutide
- 2.2.5 Dulaglutide

2.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type

2.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)

2.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Type (2018-2023)

2.3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2018-2023)

2.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application

- 2.4.1 Hospital
- 2.4.2 Pharmacy

2.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application

2.5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Market Share by Application (2018-2023)

2.5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Application (2018-2023)

2.5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2018-2023)

3 GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY COMPANY

3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Breakdown Data by Company

3.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Company (2018-2023)

3.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2018-2023)

3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Company (2018-2023)

3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2018-2023)

3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2018-2023)

3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company

3.4 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Location Distribution

3.4.2 Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY GEOGRAPHIC REGION

4.1 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Geographic Region (2018-2023)

4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country/Region (2018-2023)

4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Country/Region (2018-2023)

4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Country/Region (2018-2023)

4.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth

4.4 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth

4.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth

4.6 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth

5 AMERICAS

5.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country

5.1.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)

5.1.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)

5.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type

5.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region

6.1.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018-2023)

6.1.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2018-2023)

6.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type

6.3 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application

- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
 - 7.1.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
 - 7.1.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
- 7.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
- 7.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
 - 8.1.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
- 8.3 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies

10.3 Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies

10.4 Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors

11.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Customer

12 WORLD FORECAST REVIEW FOR GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY GEOGRAPHIC REGION

12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region

12.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Region (2024-2029)

12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Type

12.7 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Novo Nordisk

13.1.1 Novo Nordisk Company Information

13.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

13.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Novo Nordisk Main Business Overview

13.1.5 Novo Nordisk Latest Developments

13.2 AstraZeneca

13.2.1 AstraZeneca Company Information

13.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

13.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 AstraZeneca Main Business Overview

13.2.5 AstraZeneca Latest Developments

13.3 Eli Lilly

13.3.1 Eli Lilly Company Information

13.3.2 Eli Lilly Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

13.3.3 Eli Lilly Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Eli Lilly Main Business Overview

13.3.5 Eli Lilly Latest Developments

13.4 GSK

13.4.1 GSK Company Information

13.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

13.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 GSK Main Business Overview

13.4.5 GSK Latest Developments

13.5 Sanofi

13.5.1 Sanofi Company Information

13.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

13.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Sanofi Main Business Overview

13.5.5 Sanofi Latest Developments

13.6 Bristol-Myers Squibb

13.6.1 Bristol-Myers Squibb Company Information

13.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

13.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Bristol-Myers Squibb Main Business Overview

13.6.5 Bristol-Myers Squibb Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Exenatid

Table 4. Major Players of Liraglutide

Table 5. Major Players of Lixisenatide

Table 6. Major Players of Albiglutide

Table 7. Major Players of Dulaglutide

Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)

Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)

Table 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2018-2023) & (\$ million)

Table 11. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2018-2023)

Table 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2018-2023) & (US\$/Unit)

Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)

Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)

Table 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2018-2023)

Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2018-2023)

Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2018-2023) & (US\$/Unit)

Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Company (2018-2023) & (Units)

Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2018-2023)

Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2018-2023) (\$ Millions)

- Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2018-2023)
- Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 23. Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution and Sales Area
- Table 24. Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered
- Table 25. Glucagon-like peptide 1 (GLP-1)-based Therapies Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 26. New Products and Potential Entrants
- Table 27. Mergers & Acquisitions, Expansion
- Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Geographic Region (2018-2023) & (Units)
- Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Geographic Region (2018-2023)
- Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region (2018-2023)
- Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country/Region (2018-2023) & (Units)
- Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country/Region (2018-2023)
- Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country/Region (2018-2023)
- Table 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
- Table 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
- Table 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & (\$ Millions)
- Table 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
- Table 40. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
- Table 41. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)

Table 42. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018-2023) & (Units)

Table 43. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2018-2023)

Table 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2018-2023) & (\$ Millions)

Table 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2018-2023)

Table 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)

Table 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)

Table 48. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)

Table 49. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)

Table 50. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & (\$ Millions)

Table 51. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)

Table 52. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)

Table 53. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)

Table 54. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)

Table 55. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)

Table 56. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & (\$ Millions)

Table 57. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)

Table 58. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)

Table 59. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)

Table 60. Key Market Drivers & Growth Opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies

Table 61. Key Market Challenges & Risks of Glucagon-like peptide 1 (GLP-1)-based

Therapies

Table 62. Key Industry Trends of Glucagon-like peptide 1 (GLP-1)-based Therapies

Table 63. Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Material

Table 64. Key Suppliers of Raw Materials

Table 65. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List

Table 66. Glucagon-like peptide 1 (GLP-1)-based Therapies Customer List

Table 67. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2024-2029) & (Units)

Table 68. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 69. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)

Table 70. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 71. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2024-2029) & (Units)

Table 72. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 73. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)

Table 74. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)

Table 76. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2024-2029) & (Units)

Table 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 79. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2024-2029) & (Units)

Table 80. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 81. Novo Nordisk Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors

Table 82. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

Table 83. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales

(Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 84. Novo Nordisk Main Business

Table 85. Novo Nordisk Latest Developments

Table 86. AstraZeneca Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors

Table 87. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

Table 88. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 89. AstraZeneca Main Business

Table 90. AstraZeneca Latest Developments

Table 91. Eli Lilly Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors

Table 92. Eli Lilly Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

Table 93. Eli Lilly Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 94. Eli Lilly Main Business

Table 95. Eli Lilly Latest Developments

Table 96. GSK Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors

Table 97. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

Table 98. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 99. GSK Main Business

Table 100. GSK Latest Developments

Table 101. Sanofi Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors

Table 102. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

Table 103. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 104. Sanofi Main Business

Table 105. Sanofi Latest Developments

Table 106. Bristol-Myers Squibb Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors

Table 107. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications

Table 108. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 109. Bristol-Myers Squibb Main Business

Table 110. Bristol-Myers Squibb Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
- Figure 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate 2018-2029 (Units)
- Figure 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Exenatied
- Figure 10. Product Picture of Liraglutide
- Figure 11. Product Picture of Lixisenatide
- Figure 12. Product Picture of Albiglutide
- Figure 13. Product Picture of Dulaglutide
- Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type in 2022
- Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2018-2023)
- Figure 16. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Hospital
- Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Hospital (2018-2023) & (Units)
- Figure 18. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Pharmacy
- Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Pharmacy (2018-2023) & (Units)
- Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2022)
- Figure 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application in 2022
- Figure 22. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market by Company in 2022 (Units)
- Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company in 2022
- Figure 24. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market by

Company in 2022 (\$ Million)

Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company in 2022

Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Geographic Region (2018-2023)

Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region in 2022

Figure 28. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)

Figure 29. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 (\$ Millions)

Figure 30. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)

Figure 31. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 (\$ Millions)

Figure 32. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)

Figure 33. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 (\$ Millions)

Figure 34. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)

Figure 35. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 (\$ Millions)

Figure 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022

Figure 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022

Figure 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)

Figure 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)

Figure 40. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2022

Figure 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Regions in 2022

Figure 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)

Figure 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)

Figure 48. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022

Figure 56. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022

Figure 57. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)

Figure 58. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)

Figure 59. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 60. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 61. UK Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth

2018-2023 (\$ Millions)

Figure 64. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022

Figure 65. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022

Figure 66. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)

Figure 67. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)

Figure 68. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 69. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Israel Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 72. GCC Country Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies in 2022

Figure 74. Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies

Figure 75. Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies

Figure 76. Channels of Distribution

Figure 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Forecast by Region (2024-2029)

Figure 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Region (2024-2029)

Figure 79. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2024-2029)

Figure 80. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Type (2024-2029)

Figure 81. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Application (2024-2029)

Figure 82. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G8A5776EFA26EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8A5776EFA26EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970